Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afabicin in Bone or Joint Infection Due to Staphylococcus
NCT03723551Phase 2Terminated
- Sponsor
- Debiopharm
- Start
- Feb 2019
- Primary completion
- Apr 2025
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of afabicin (8 cohorts), sponsored by Debiopharm. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Number of Participants With Grade Shift From Baseline in Hematology Parameters Based on NCI-CTCAE v4.03 and 4 more. Started Feb 2019; status: terminated.
02
Drugs
afabicin
Beyond the preview
Go deeper on NCT03723551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03723551.